Introduction of a biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis

Ook onderdeel van:

Kennisagenda: -
Implementatieagenda: -

Introduction of a biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis

Zorgevaluatie Nederland zorgevaluatienederland.nl

Referenties